title: Pilot trial of onabotulinumtoxina (Botox) in moderate to severe restless legs syndrome.
abstract: OBJECTIVE
  To evaluate the potential of onabotulinum toxin A (Botox®, Allergan, Inc., Irvine, California) in the treatment of restless legs syndrome (RLS).
  
  
  METHODS
  A single-arm, open-label pilot trial of onabotulinum toxin A was conducted to determine its usefulness as an injectable treatment for RLS.
  
  
  RESULTS
  The primary outcome measure, change in score on the International Restless Legs Syndrome Scale, showed a statistically significant improvement in RLS during the first 4 weeks after treatment. Two of the secondary outcome measures, pain (measured using a visual analog scale) and patients' global impression of severity of illness also showed improvement.
  
  
  CONCLUSIONS
  Onabotulinum toxin A warrants further study in RLS. Increasing the drug dosage, changing the dosing schedule, and increasing the number of injection sites may result in greater activity and longer duration of action.
authors: Booth Gardner Parkinson's Care Center, Evergreen Neuroscience Institute , Evergreen Hospital Medical Center, Kirkland, WA 98034, USA. pagarwal@evergreenhealthcare.org
authors: Pinky
authors: P
authors: Agarwal
authors: Cherri
authors: C
authors: Sia
authors: Narendra
authors: N
authors: Vaish
authors: Ina
authors: I
authors: Roy-Faderman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects; D017060:Patient Satisfaction; D010865:Pilot Projects; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A